新型肿瘤标志物的临床应用——前景与挑战

doi:10.3969/j.issn.1673-8640.2023.04.001

摘要/Abstract

摘要：

早期诊断和个体化精准治疗是提高肿瘤患者生存率、改善生活质量和延长生存期的关键。近年来，随着液体活检技术的发展，越来越多的新型肿瘤标志物被发现，在肿瘤诊断、预后判断和治疗监测等方面表现出较大的潜力，并且部分指标已应用于临床实践。未来研究应重点解决阻碍新型肿瘤标志物实现临床转化的难题，促使更多具有临床应用前景的液体活检指标能够优化肿瘤患者的诊疗过程，从而减轻患者疾病负担。

关键词: 肿瘤标志物, 循环肿瘤细胞, 循环肿瘤DNA甲基化, 非编码RNA, 细胞外基质

Abstract:

Early diagnosis and individualized precise treatment are the keys to improve the survival rate and the quality of life and prolong the survival time of cancer patients. In the recent years，with the development of liquid biopsy technology，more and more novel tumor biomarkers have been found，showing potential in tumor diagnosis，prognostic judgment and treatment monitoring，and some indicators have been put into clinical practice. Future researches should focus on solving the problems that hinder the clinical transformation of novel tumor biomarkers，and promote more liquid biopsy indicators with clinical application prospects to optimize the diagnosis and treatment process of cancer patients，thereby reducing their disease burden.

Key words: Tumor biomarker, Circulating tumor cell, Circulating tumor DNA methylation, Non-coding RNA, Extracellular matrix

中图分类号:

R446.1

高锋. 新型肿瘤标志物的临床应用——前景与挑战[J]. 检验医学, 2023, 38(4): 303-306.

GAO Feng. Clinical application of novel tumor biomarkers：prospects and challenges[J]. Laboratory Medicine, 2023, 38(4): 303-306.

参考文献 33.

1.	IGNATIADIS M, SLEDGE G W, JEFFREY S S. Liquid biopsy enters the clinic-implementation issues and future challenges[J]. Nat Rev Clin Oncol, 2021, 18(5):297-312. DOI
2.	RING A, NGUYEN-STRÄULI B D, WICKI A, et al. Biology, vulnerabilities and clinical applications of circulating tumour cells[J]. Nat Rev Cancer, 2023, 23(2):95-111. DOI
3.	LUO H, WEI W, YE Z, et al. Liquid biopsy of methylation biomarkers in cell-free DNA[J]. Trends Mol Med, 2021, 27(5):482-500. DOI PMID
4.	SLACK F J, CHINNAIYAN A M. The role of non-coding rnas in oncology[J]. Cell, 2019, 179(5):1033-1055. DOI PMID
5.	FREZZETTI D, DE LUCA A, NORMANNO N. Extracellular matrix proteins as circulating biomarkers for the diagnosis of non-small cell lung cancer patients[J]. J Thorac Dis, 2019, 11(Suppl 9):S1252-S1256. DOI URL
6.	DENG Z, WU S, WANG Y, et al. Circulating tumor cell isolation for cancer diagnosis and prognosis[J]. EBioMedicine, 2022, 83:104237. DOI URL
7.	ALIX-PANABIÈRES C, PANTEL K. Clinical applications of circulating tumor cells and circulating tumor DNA as liquid biopsy[J]. Cancer Discov, 2016, 6(5):479-491. DOI URL
8.	KELLER L, PANTEL K. Unravelling tumour heterogeneity by single-cell profiling of circulating tumour cells[J]. Nat Rev Cancer, 2019, 19(10):553-567. DOI PMID
9.	WANG Y, KIM T H, FOULADDEL S, et al. PD-L1 expression in circulating tumor cells increases during radio(chemo)therapy and indicates poor prognosis in non-small cell lung cancer[J]. Sci Rep, 2019, 9(1):566. DOI PMID
10.	BIDARD F C, PEETERS D J, FEHM T, et al. Clinical validity of circulating tumour cells in patients with metastatic breast cancer:a pooled analysis of individual patient data[J]. Lancet Oncol, 2014, 15(4):406-414. DOI URL
11.	SCHER H I, HELLER G, MOLINA A, et al. Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancer[J]. J Clin Oncol, 2015, 33(12):1348-1355. DOI PMID
12.	HELLER G, MCCORMACK R, KHEOH T, et al. Circulating tumor cell number as a response measure of prolonged survival for metastatic castration-resistant prostate cancer:a comparison with prostate-specific antigen across five randomized phase Ⅲ clinical trials[J]. J Clin Oncol, 2018, 36(6):572-580.
13.	AHN J C, TENG P C, CHEN P J, et al. Detection of circulating tumor cells and their implications as a biomarker for diagnosis,prognostication,and therapeutic monitoring in hepatocellular carcinoma[J]. Hepatology, 2021, 73(1):422-436. DOI URL
14.	ZHANG W, LI N, LIN L, et al. Metabolism-based capture and analysis of circulating tumor cells in an open space[J]. Anal Chem, 2021, 93(18):6955-6960. DOI PMID
15.	KHOO B L, GRENCI G, JING T, et al. Liquid biopsy and therapeutic response:circulating tumor cell cultures for evaluation of anticancer treatment[J]. Sci Adv, 2016, 2(7):e1600274. DOI URL
16.	KANWAL R, GUPTA K, GUPTA S. Cancer epigenetics:an introduction[J]. Methods Mol Biol, 2015, 1238:3-25.
17.	SPAINHOUR J C, LIM H S, YI S V, et al. Correlation patterns between DNA methylation and gene expression in the cancer genome atlas[J]. Cancer Inform, 2019, 18:1176935119828776.
18.	MORAN S, MARTÍNEZ-CARDÚS A, SAYOLS S, et al. Epigenetic profiling to classify cancer of unknown primary:a multicentre,retrospective analysis[J]. Lancet Oncol, 2016, 17(10):1386-1395. DOI URL
19.	LAMB Y N, DHILLON S. Epi proColon^® 2.0 CE:a blood-based screening test for colorectal cancer[J]. Mol Diagn Ther, 2017, 21(2):225-232. DOI URL
20.	ZHANG C, YU W, WANG L, et al. DNA methylation analysis of the SHOX2 and RASSF1A panel in bronchoalveolar lavage fluid for lung cancer diagnosis[J]. J Cancer, 2017, 8(17):3585-3591. DOI PMID
21.	XIE Y, ZHANG Y, DU L, et al. Circulating long noncoding RNA act as potential novel biomarkers for diagnosis and prognosis of non-small cell lung cancer[J]. Mol Oncol, 2018, 12(5):648-658. DOI PMID
22.	JENIKE A E, HALUSHKA M K. MiR-21:a non-specific biomarker of all maladies[J]. Biomark Res, 2021, 9(1):18. DOI
23.	ASHIRBEKOV Y, ABAILDAYEV A, OMARBAYEVA N, et al. Combination of circulating miR-145-5p/miR-191-5p as biomarker for breast cancer detection[J]. PeerJ, 2020, 8:e10494. DOI URL
24.	NG E K, LI R, SHIN V Y, et al. Circulating microRNAs as specific biomarkers for breast cancer detection[J]. PLoS One, 2013, 8(1):e53141. DOI URL
25.	KARAMANOS N K, THEOCHARIS A D, PIPERIGKOU Z, et al. A guide to the composition and functions of the extracellular matrix[J]. FEBS J, 2021, 288(24):6850-6912. DOI PMID
26.	GIUSSANI M, TRIULZI T, SOZZI G, et al. Tumor extracellular matrix remodeling:new perspectives as a circulating tool in the diagnosis and prognosis of solid tumors[J]. Cells, 2019, 8(2):81. DOI URL
27.	ALASEEM A, ALHAZZANI K, DONDAPATI P, et al. Matrix metalloproteinases:a challenging paradigm of cancer management[J]. Semin Cancer Biol, 2019, 56:100-115. DOI URL
28.	NECULA L, MATEI L, DRAGU D, et al. Collagen family as promising biomarkers and therapeutic targets in cancer[J]. Int J Mol Sci, 2022, 23(20):12415. DOI URL
29.	MOON P G, LEE J E, CHO Y E, et al. Fibronectin on circulating extracellular vesicles as a liquid biopsy to detect breast cancer[J]. Oncotarget, 2016, 7(26):40189-40199. DOI URL
30.	RESOVI A, BANI M R, PORCU L, et al. Soluble stroma-related biomarkers of pancreatic cancer[J]. EMBO Mol Med, 2018, 10(8):e8741. DOI URL
31.	CHEN L, HUAN X, XIAO G H, et al. Osteopontin and its downstream carcinogenic molecules:regulatory mechanisms and prognostic value in cancer progression[J]. Neoplasma, 2022, 69(6):1253-1269. DOI URL
32.	WU M, CAO M, HE Y, et al. A novel role of low molecular weight hyaluronan in breast cancer metastasis[J]. FASEB J, 2015, 29(4):1290-1298. DOI PMID
33.	ZHANG G, LU R, WU M, et al. Colorectal cancer-associated-6 kDa hyaluronan serves as a novel biomarker for cancer progression and metastasis[J]. FEBS J, 2019, 286(16):3148-3163. DOI URL

[1]	周韵斓, 沈立松. 液体活检标志物在非小细胞肺癌中的临床应用和挑战[J]. 检验医学, 2023, 38(9): 807-811.
[2]	赵沱, 白鹏飞, 孙婧, 程涛. 血清lncRNA NEAT1在急性心肌梗死患者中的表达及其临床意义[J]. 检验医学, 2023, 38(9): 897-900.
[3]	卫明珠, 潘继文, 罗锐, 陈俊辉. 凝血4项和肿瘤标志物对乙型肝炎相关肝癌的辅助诊断价值[J]. 检验医学, 2023, 38(9): 901-904.
[4]	王腾飞, 陈珊, 安和兵, 周蕾. 急性白血病患者外周血lncRNA CRNDE、miR-384表达及其临床意义[J]. 检验医学, 2023, 38(7): 686-691.
[5]	张敏, 王彬宇, 迟伟群, 刘禹. 外泌体非编码RNA作为疾病诊断生物标志物的研究进展[J]. 检验医学, 2023, 38(6): 594-598.
[6]	吴炯, 胡嘉华, 施美芳, 刘涛, 戴洁, 卢忻怡, 邹政. 前列腺癌生物标志物研究进展[J]. 检验医学, 2023, 38(2): 190-195.
[7]	周福荣, 李龑杼, 刘勇敢. lncRNA SNP在结直肠癌易感性预测和预后评估中的应用[J]. 检验医学, 2023, 38(12): 1206-1210.
[8]	郭霜, 刘红莉, 李娅. EB病毒相关胃癌迁移、侵袭相关miRNA和lncRNA研究进展[J]. 检验医学, 2023, 38(10): 987-996.
[9]	王瑞娟, 李超, 段丽娟, 尚淼, 杨如玉. lncRNA RBM5-AS1在急性髓系白血病中的表达及其临床意义[J]. 检验医学, 2023, 38(1): 39-45.
[10]	汪雨卿, 张越, 徐稳, 崔中奇. 铁死亡相关lncRNA结肠癌预后风险模型的构建及临床应用[J]. 检验医学, 2022, 37(8): 720-728.
[11]	柳行强, 宁立芬, 李琳, 陈忠成. FR⁺-CTC、ANXA2、ProGRP与肺癌临床病理特征的相关性[J]. 检验医学, 2022, 37(8): 735-740.
[12]	冀叶, 袁小笋, 张蕾, 马慧利, 薛永飞, 李长生, 张敬伟, 任中海, 张腾飞. lncRNA HULC在乳头状甲状腺癌组织中的表达及意义[J]. 检验医学, 2022, 37(7): 605-609.
[13]	冀叶, 袁小笋, 张蕾, 马慧利, 董薇, 李长生, 张敬伟, 任中海, 张怡飞. lncRNA SNHG15在胃癌组织中的表达及临床意义[J]. 检验医学, 2022, 37(5): 409-412.
[14]	俞琦, 孙懿, 王琼丽, 蔡逸婷, 李莉. 外周血循环肿瘤细胞形态学分析技术在临床检验中的应用[J]. 检验医学, 2022, 37(3): 264-269.
[15]	周焕, 唐颖, 杜翠萍, 杨扬, 冯会杰, 邱淼欣, 闫佩毅, 蔡骁垚, 金姝. lncRNA SNHG5对人类下咽癌细胞转录组学的影响及意义[J]. 检验医学, 2022, 37(3): 281-287.